



Figure 2: Overall survival stratified for busulfan pharmacokinetic targeting. The targeted group 3-year OS of 79.9% (95% CI 69.4% - 90.4%) compared with the untargeted group: 75.0% (95% CI 62.5% - 87.5%). P value = 0.6